Want to join the conversation?
$CELG affirmed its 2020 long-term financial targets of net products sales exceeding $21Bil, with Hematology franchise to exceed $14.8Bil, Oncology franchise to exceed $2.2Bil, and I&I franchise to exceed $4Bil. Adjusted EPS is projected to exceed $13.
$AAL is getting stronger into Dec. after a strong Nov..!! I’m feeling confident about their 4Q revenue forecast for a margin rise.
$KO’s CEO Muhtar Kent to step down next year. COO James Quincey will take the helm in what is already a smooth sailing scenario. And as always, shares reflect by growing 2% after the market opened.